After the birth of the first genome-edited babies in China, regulators, researchers, and bioethics experts seek ways to ban clinical use of germline editing, in order to protect the innovative field from misuse for human enhancement and side effect-prone application forgene correction and human enhancement.
New CEO at Morphosys
AppointmentsGermany-based MorphoSys AG announced that its Supervisory Board has today appointed Jean-Paul Kress, M.D., as its new Chief Executive Officer. The appointment will take effect on September 1, 2019.
Sanifit raise €72.2m to push SNF472 development
Latest NewsGenfit in $228m deal with Terns Pharmaceuticals
Latest NewsVesalius Biocapital III Fund closes at €120 million
Latest NewsErytech Pharma SA bags US$57m from SQZ Biotechnologies
Latest NewsSanofi/Regeneron’s IL-33 blocker meets endpoint in POC study
Latest NewsResearchers and bioethicists to pause germline editing
BackgroundAfter the birth of the first genome-edited babies in China, regulators, researchers, and bioethics experts seek ways to ban clinical use of germline editing, in order to protect the innovative field from misuse for human enhancement and side effect-prone application forgene correction and human enhancement.
Karo Pharma acquires Trimb AB
Latest NewsUK biotech to make proteins from carbon dioxide emissions
Latest NewsDeep Branch Biotechnology Ltd. from Nottingham has started a feasibility study with the British energy supplier Drax Group. The technology to be analysed converts carbon dioxide emitted by power stations into protein that could be used for feeding fish and livestock.
GM proponents grill German government
Latest NewsGerman GM proponents have taken action against discrimination of food products generated by gene editing.